SOURCE: Medifocus, Inc.

September 08, 2014 08:30 ET

SeeThruEquity Initiates Research Coverage on Medifocus Inc. With Target Price of $0.52

COLUMBIA, MD and TORONTO, ON--(Marketwired - Sep 8, 2014) - Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today that SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, has initiated coverage on Medifocus, Inc. with a target price of $0.52. The report is available at: http://www.seethruequity.com/.

Dr. Augustine Y. Cheung, President and CEO of Medifocus, commented, "We are pleased that SeeThruEquity started coverage on Medifocus and it sees the value of our business model and technology platforms. SeeThruEquity is of the strong opinion that our APA 1000 Breast Cancer Treatment System could significantly drive valuation of the Company due to strong interest shown by the investment community in novel treatment for breast cancer patients."

Dr. Cheung added, "While we will continue to grow our Prolieve® business, we will allocate more resources to accelerate the pivotal Phase III clinical trial for the APA 1000 Breast Cancer Treatment System. In addition to the current Phase III clinical trial, we believe our Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus, can be used to treat early stage breast cancer tumors and recurrent chest wall (RCW) cancer. Our goal is to increase our exposure to the investment community and increase Medifocus' value."

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson Reuters One (First Call), CapitalIQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street. For more information please visit www.seethruequity.com

About Medifocus, Inc.

Medifocus owns two fully developed technology platforms with comprehensive United States and international patent protection: (i) The Endo-thermotherapy Platform-a catheter-basis focused heat technology platform that utilizes natural body openings to deliver precise microwave thermotherapy to the diseased sites. The United States Food and Drug Administration (FDA) approved Prolieve Thermodilatation System for the treatment of Benign Prostatic Hyperplasia (BPH) was developed based on the Endo-thermotherapy and is currently generating revenue; and (ii) the Adaptive Phased Array (APA) Microwave Focusing Platform, invented by the Massachusetts Institute of Technology, licensed to Medifocus directs precisely focused microwave energy at the tumor center to induce shrinkage or eradication of tumors without undue harm to surrounding tissue. Medifocus' APA 1000 Breast Cancer Treatment System, developed from the APA technology platform, has received approval from the FDA and Health Canada to conduct the pivotal Phase III clinical trials. Medifocus believes that these two technology platforms can provide the design basis for the development of multiple cancer treatment systems for surface, subsurface and deep seated localized and regional cancers. Please visit www.medifocusinc.com, www.prolieve.com and http://www.facebook.com/pages/Medifocus-Inc-Company-Page/546315028715627 for more details.

Forward-Looking Statements and Information

This news release contains "forward-looking statements" and "forward-looking information", which may not be based on historical facts. Forward-looking statements and forward-looking information, include, but are not limited to, information and statements with respect the structure and the proceeds of the Offering and the expected use of the proceeds. Forward-looking statements are frequently characterized by words such as "plan," "expect," "project," "intend," "believe," "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made. Such forward-looking statements and forward-looking information involve known and unknown risks, uncertainties and other factors that may cause the actual results events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or forward-looking information. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements and forward-looking information. Except as required by applicable securities laws, Medifocus disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements or forward-looking information contained herein to reflect future results, events or developments.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information